Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022

Sankalp Arora; Palash Asawa; Nilansh Kataria; Lizza E L Hendriks; Aakash P Desai

doi:10.1080/07357907.2022.2077566

Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022

Sankalp Arora
, Palash Asawa
, Nilansh Kataria
, Lizza E L Hendriks
, Aakash P Desai^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

106 Downloads (Pure)

Abstract

The recently concluded European Lung Cancer Congress 2022 (ELCC22) showcased some very exciting data, with more than 200 abstracts presented during the meeting. Through this review, we focus on selected clinically relevant abstracts that in our opinion represent significant updates in the current management of non-small cell lung cancer (NSCLC). Here, we summarize the updates in surgical management, adjuvant therapy and therapy for advanced stage NSCLC and put these advances in context of current clinical standard of care.

Original language	English
Pages (from-to)	577-589
Number of pages	13
Journal	Cancer Investigation
Volume	40
Issue number	7
Early online date	29 Jun 2022
DOIs	https://doi.org/10.1080/07357907.2022.2077566
Publication status	Published - 9 Aug 2022

Keywords

1ST-LINE TREATMENT
CHEMOTHERAPY
DOUBLE-BLIND
GEFITINIB
MULTICENTER
MUTATIONS
Non-small cell lung cancer
OSIMERTINIB
PHASE-III
SURVIVAL
adjuvant
advanced
metastatic

Access to Document

10.1080/07357907.2022.2077566

Full TextFinal published version, 1.52 MBLicence: Taverne

Cite this

@article{323012fc0b164921ad7015a802674d55,

title = "Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022",

abstract = "The recently concluded European Lung Cancer Congress 2022 (ELCC22) showcased some very exciting data, with more than 200 abstracts presented during the meeting. Through this review, we focus on selected clinically relevant abstracts that in our opinion represent significant updates in the current management of non-small cell lung cancer (NSCLC). Here, we summarize the updates in surgical management, adjuvant therapy and therapy for advanced stage NSCLC and put these advances in context of current clinical standard of care.",

keywords = "1ST-LINE TREATMENT, CHEMOTHERAPY, DOUBLE-BLIND, GEFITINIB, MULTICENTER, MUTATIONS, Non-small cell lung cancer, OSIMERTINIB, PHASE-III, SURVIVAL, adjuvant, advanced, metastatic",

author = "Sankalp Arora and Palash Asawa and Nilansh Kataria and Hendriks, \{Lizza E L\} and Desai, \{Aakash P\}",

note = "Funding Information: SA, PA, NK and AD do not have any disclosures. LH – Outside of current manuscript: research funding Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda (all institutions, Beigene under negotiation); advisory board: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Merck, Novartis, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD, Lilly, AstraZeneca (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars/podcast: Benecke, Medtalks, VJOncology (self), high5oncology, Takeda (institution); interview sessions funded by Roche Genentech, Bayer, Lilly (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD/Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, Mirati, Abbvie. Publisher Copyright: {\textcopyright} 2022 Taylor \& Francis Group, LLC.",

year = "2022",

month = aug,

day = "9",

doi = "10.1080/07357907.2022.2077566",

language = "English",

volume = "40",

pages = "577--589",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor \& Francis Group LLC Philadelphia",

number = "7",

}

TY - JOUR

T1 - Management of Non-Small Cell Lung Cancer

T2 - Updates from the European Lung Cancer Congress 2022

AU - Arora, Sankalp

AU - Asawa, Palash

AU - Kataria, Nilansh

AU - Hendriks, Lizza E L

AU - Desai, Aakash P

N1 - Funding Information: SA, PA, NK and AD do not have any disclosures. LH – Outside of current manuscript: research funding Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda (all institutions, Beigene under negotiation); advisory board: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Merck, Novartis, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD, Lilly, AstraZeneca (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars/podcast: Benecke, Medtalks, VJOncology (self), high5oncology, Takeda (institution); interview sessions funded by Roche Genentech, Bayer, Lilly (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD/Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, Mirati, Abbvie. Publisher Copyright: © 2022 Taylor & Francis Group, LLC.

PY - 2022/8/9

Y1 - 2022/8/9

N2 - The recently concluded European Lung Cancer Congress 2022 (ELCC22) showcased some very exciting data, with more than 200 abstracts presented during the meeting. Through this review, we focus on selected clinically relevant abstracts that in our opinion represent significant updates in the current management of non-small cell lung cancer (NSCLC). Here, we summarize the updates in surgical management, adjuvant therapy and therapy for advanced stage NSCLC and put these advances in context of current clinical standard of care.

AB - The recently concluded European Lung Cancer Congress 2022 (ELCC22) showcased some very exciting data, with more than 200 abstracts presented during the meeting. Through this review, we focus on selected clinically relevant abstracts that in our opinion represent significant updates in the current management of non-small cell lung cancer (NSCLC). Here, we summarize the updates in surgical management, adjuvant therapy and therapy for advanced stage NSCLC and put these advances in context of current clinical standard of care.

KW - 1ST-LINE TREATMENT

KW - CHEMOTHERAPY

KW - DOUBLE-BLIND

KW - GEFITINIB

KW - MULTICENTER

KW - MUTATIONS

KW - Non-small cell lung cancer

KW - OSIMERTINIB

KW - PHASE-III

KW - SURVIVAL

KW - adjuvant

KW - advanced

KW - metastatic

U2 - 10.1080/07357907.2022.2077566

DO - 10.1080/07357907.2022.2077566

M3 - Article

C2 - 35561313

SN - 0735-7907

VL - 40

SP - 577

EP - 589

JO - Cancer Investigation

JF - Cancer Investigation

IS - 7

ER -

Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022

Abstract

Keywords

Access to Document

Fingerprint

Cite this